mizoribine has been researched along with lamivudine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Akimoto, T; Higashizawa, T; Inoue, M; Isoda, N; Kusano, E; Muto, S; Nishino, K; Otake, T; Saito, O; Sugano, K; Takahashi, H; Tanaka, A | 1 |
2 other study(ies) available for mizoribine and lamivudine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases.
Topics: Aged; Female; Glomerulonephritis, Membranous; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Prednisolone; Ribonucleosides; Treatment Outcome | 2011 |